Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects Evotec is providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries.
Evotec's proprietary projects specialise in finding new treatments for diseases of the Central Nervous System (CNS). The focus of research is on major CNS related conditions, including sleep disorders, Alzheimer's disease, pain management and smoking cessation - fast growing therapeutic areas with large unmet medical needs. Evotec has a diverse product pipeline with candidates at various stages of development. The Company's most advanced product candidate, which has recently completed Phase II clinical trials with excellent results, is EVT 201, a partial positive allosteric modulator of the GABAA receptor complex for the treatment of insomnia. Through selective in-licensing and the use of its platform for internal discovery efforts, Evotec intends to further develop and expand its preclinical and clinical CNS pipeline for partnering.
- Focus : Manufacturer
- Employees: 501-1000
News about Evotec
04-Nov-2022 | Business
Evotec completes acquisition of Central Glass Germany
Evotec SE announced that the acquisition of Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd., signed in ...
20-Sep-2022 | Manufacturing
Evotec initiates ground-breaking for new biologics facility J.POD® Toulouse
Evotec SE officially launched the construction of its J.POD® biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® Toulouse ...
26-Aug-2022 | Business
Evotec expands clinical and commercial drug substance manufacturing with acquisition of Central Glass Germany
Evotec SE announced that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass ...
07-Jul-2022 | Cooperation
Three partners committed to combat AMR
Evotec SE, Boehringer Ingelheim and bioMérieux announced that they have formed a joint venture to create the next generation of antimicrobials along with ...
05-Jul-2022 | Business
Evotec completes acquisition of Rigenerand
Evotec SE announced that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed. Based out of Medolla, Italy, the cell ...
14-Jun-2022 | Cooperation
Evotec enters a drug discovery collaboration with Janssen
Evotec SE announced that the Company has entered a drug discovery collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies ...
31-May-2022 | Business
Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
Evotec SE announced the signing of a definitive agreement under which Evotec will acquire 100% of the capital of Rigenerand Srl, a leading cell technology ...